Hiv, HSV
Conditions
Keywords
HIV, TAF, EVG, Prevention, Vaginal Insert
Brief summary
The purpose of this Phase I study is to assess the safety, pharmacokinetics, and pharmacodynamics of a combination vaginal insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG). This study will be the first-in-human study for a vaginally administered TAF/EVG insert and will evaluate safety, PK and PD after a single dose. It is hypothesized that the combination insert will be safe and well-tolerated by study participants and that the insert will offer an expanded window of preventive activity and a regimen with flexibility and forgiveness.
Detailed description
This Phase I study aims to complete at least 16 healthy, non-pregnant, HIV-uninfected women aged 18-50 years who are not at risk for pregnancy and are at low risk for sexually transmitted infections (STIs) at one clinical site. The study will examine the safety, PK, PD, disintegration, and acceptability of vaginal inserts containing the combination of tenofovir alafenamide (TAF) and elvitegravir (EVG). Participants will be randomized (1:1) into one of two sample collection time point groups: \[Timepoint group 1: 4 and 48 hours after using the single combination insert\] or \[Timepoint group 2: 24 and 72 hours after using the single combination insert\] There will be 5 scheduled visits: Visit 1 (Screening/Enrollment): Volunteers will be consented and undergo tests and procedures to confirm they are eligible to continue in the study. Visit 2 (Baseline): Once it has been confirmed that participants are eligible and willing to continue, they will be asked to complete a short baseline questionnaire about the insert. Participants will be randomized to Timepoint group 1 or Timepoint group 2 for sample collection and will then undergo baseline sampling \[cervicovaginal (CV) fluid and tissue\]. Visit 3 (Insert use and sampling): Participants will use a single combination insert of TAF/EVG in the clinic. Depending upon timepoint randomization, percentage disintegration of the vaginal inserts will be assessed at either 4 hours or 24 hours, and PK and PD sample collection (plasma, CV fluid, and CV tissue) will occur. Participants will also be asked to complete a short acceptability questionnaire. Visit 4 (Post-Dose Sampling): Participants will undergo sample collection of blood for safety and PK evaluations; and CV fluid and CV tissue for PK at either 48 hours or 72 hours depending upon timepoint randomization. Visit 5 (Post-Dose Sampling): Participants will undergo a PK sample collection (CV fluid) 7 (±2) days post dose. Participants will be asked about adverse events and concomitant medications taken. Participants will then be exited from the study, unless they have symptoms that require follow-up. There will be 5 scheduled visits over approximately 1-3 months.
Interventions
1 combination vaginal insert (20mg TAF/16mg EVG)
Sponsors
Eastern Virginia Medical School
United States Agency for International Development (USAID)
CONRAD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
All participants will use a single combination TAF/EVG vaginal insert.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 to 50 years, inclusive 2. General good health (by volunteer history and per investigator judgment) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, bone disease, and diabetes) and with an intact uterus and cervix. 3. History of regular menstrual cycles, by volunteer report (for cycling women) 4. History of Pap smears and follow-up consistent with standard clinical practice as outlined in the Study Manual or willing to undergo a Pap smear at Visit 1 5. Able to communicate in spoken and written English 6. Willing to give voluntary consent and sign an informed consent form 7. Willing and able to comply with protocol requirements, including abstaining from vaginal activity and product use at specified times 8. Must be protected from pregnancy by one of the following: * Hormonal methods, except vaginal rings and DMPA * Copper IUD * Sterilization of participant or partner * Consistent condom use * Abstinence from penile-vaginal intercourse * Same sex relationship 9. If in a relationship, must be in a mutually monogamous relationship with a partner who is not known to be HIV positive and has no known risk of sexually transmitted infections (STIs)
Exclusion criteria
1. Positive pregnancy test or plans to become pregnant during the course of the study 2. Currently breastfeeding or planning to breastfeed during the course of the study 3. History of sensitivity/allergy to any component of the study product, topical anesthetic, or to both silver nitrate and Monsel's solution 4. In the last three months, diagnosed with or treated for any STI (For HSV, ideally no outbreaks in the past year. More than two outbreaks in previous 12 month period is exclusionary.) 5. Positive test for Trichomonas vaginalis (TV), Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), HIV, or Hepatitis B surface antigen (HBsAg) 6. Symptomatic bacterial vaginosis (BV) 7. Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting/bleeding, discharge, etc.) 8. Known blood disorder, including deep vein thrombosis (DVT) and pulmonary embolism (PE), or those that could lead to prolonged or continuous bleeding with biopsy 9. NSAIDS, systemic corticosteroids (e.g. dexamethasone), Endothelin Receptor Antagonists (e.g bosentan), antibiotics, Anticonvulsants (e.g. carbamazepine, oxcarbazepine, phenobarbital, phenytoin), Antimycobacterials (Rifbutin, Rifampin, Rifapentine) anticoagulants or other drugs known to prolong bleeding and/or clotting, antifungals (i.e ketoconazole), or antivirals or antiretroviral (e.g. acyclovir, valacyclovir, Viread®, Atripla®, Emtriva®, or Complera®), St. John's Wort or drugs that may interact with TAF or EVG as specified in the Vitekta and Vemlidy Investigator Brochure, should not be used during the study. 10. Current or anticipated chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetominophen for the duration of the study. 11. Participation in any other investigational trial with use of a drug/device within the last 30 days or planned participation in any other investigational trial with use of a drug/device during the study 12. Grade 2 or higher laboratory abnormality, per the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events, or clinically significant laboratory abnormality as determined by the clinician 13. Abnormal finding on laboratory or physical examination or a social or medical condition in the volunteer which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Drug Concentrations of EVG, TFV, TFV-DP, and TAF | From dosing to 72 hours post-dose | Concentrations of EVG, TFV, TFV-DP, TAF in CV tissue |
| Number of Participants with Grade 2 or higher treatment-emergent adverse events (TEAEs) | Changes from baseline up to a maximum of 12 days post-dose | TEAEs are defined as adverse events starting or worsening after administration of the study product; Grade is determined by the DAIDS Grading Table |
| Number of participants with adverse events | Changes from baseline up to a maximum of 12 days post-dose | Adverse events for this outcome are those that are product-related urogenital in nature |
| systemic laboratory assessments | Changes from baseline up to 72 hours post-dose | Number of participants with abnormal serum chemistry |
| Systemic Laboratory Assessments | Changes from baseline up to 72 hours post-dose | Number of participants with abnormal complete blood count |
| Drug Concentrations of EVG, TFV, and TAF | From dosing to 72 hours post-dose | Concentrations of EVG, TFV, and TAF in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent (%) inhibition of HIV in vaginal cell assay (Anti-HIV activity) | Changes from baseline to 24 hours post-dose | Anti-HIV activity in CV fluid |
| Percent (%) inhibition of HSV in vaginal cell assay (Anti-HSV activity) | Changes from baseline to 24 hours post-dose | Anti-HSV activity in CV fluid |
| Number of participant tissue samples demonstrating HIV-1 infectivity | Changes from baseline to 4 hours post-dose | p24 antigen production in CV tissue infected with HIV-1 ex vivo |
| Disintegration of insert | At 4 or 24 hours post-dose (per randomized time point) | Percent (%) disintegration at the first evaluation after dosing |
| Acceptability of insert: questionnaire | At baseline and at 48 or 72 hours post-dose (per randomized time point) | Responses to key questions on acceptability questionnaire (including prior experience with vaginal product use, initial and post-use impressions of insert, dissolution time, discharge amounts, and feelings about real-world use if insert was available for use |
Other
| Measure | Time frame | Description |
|---|---|---|
| HSV infectivity | Changes from baseline to 24 hours post-dose | HSV DNA fold change after ex vivo infection of CV tissue with HSV |
Countries
United States
Outcome results
None listed